NuChem Therapeutics Acquires Amplia Pharmatek to Advance Preclinical Drug Discovery and Early-Stage Development

VCBeat (WeChat ID: vcbeat) has learned that on October 31, 2019, NuChem Therapeutics, a Canadian CRO company, completed its acquisition of Amplia Pharmatek. No financial terms of the transaction were disclosed.

NuChem Therapeutics is a privately held CRO founded in 2011 and headquartered in Montreal, Quebec, Canada. Specializing in medicinal chemistry, the company engages in the custom synthesis of small molecules and peptides. It provides a range of services to support the biotechnology and pharmaceutical industries, helping to identify and optimize small-molecule candidates for drug discovery and early-stage development.

NuChem Therapeutics specializes in medicinal chemistry and drug discovery biology, offering customized compound synthesis, structure-activity relationship (SAR) design, DMPK services, computational drug design, and analytical development services to help clients advance their projects rapidly and efficiently.

The senior team members at NuChem Therapeutics possess extensive experience in preclinical drug development within the pharmaceutical and biotechnology sectors, focusing on therapeutic agents for conditions such as inflammation, diabetes, obesity, infectious diseases, and cancer. Since its establishment in 2011, NuChem Therapeutics has contributed to the discovery of multiple new drug candidates, facilitating the approval and commercial launch of several medications, including Singulair®, Arcoxia®, and Tredaptive®.

Amplia Pharmatek, established in September 2009 and headquartered in Montreal, Quebec, Canada, is an innovative provider of preclinical drug discovery and development services. The company is dedicated to delivering services in discovery biology (biochemistry, cell biology, molecular biology), in vivo pharmacology, pharmacokinetic studies, and toxicology assessments.

Amplia Pharmatek adheres to the “Four Big C’s” as its corporate principles: customer-centricity, close collaboration with clients, comprehensive services ranging from candidate drug discovery to drug repurposing, and strict on-time project delivery.

Following this acquisition, Amplia Pharmatek and NuChem Therapeutics will form a growing team of more than 60 employees, delivering a broad range of services to clients.

Marc LeBel, President of NuChem Therapeutics, stated, “The combination of Amplia and NuChem will enable us to better serve our customers, which remains our top priority. With our dedicated team of scientists and a brand-new facility, the future looks bright.”

Daniel Guay, CSO of NuChem Therapeutics, added, “We are delighted to partner with Dr. Li and the Amplia Pharmatek team. The complementarity between our two teams will create synergies in our respective services, propelling the company to a new level.”

Dr. Zuomei Li, founder of Amplia Pharmatek, stated, “The Amplia team is delighted to join the Nuchem family. Our experts will provide seamless services ranging from lead molecule identification to early-stage development of drug candidates for multiple disease indications.”

(Compiled by Jiang Ying)